1Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies: part Ⅰ. Circulation, 2003,108:1664-1672.
2Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies: part Ⅱ. Circulation, 2003,108:1772-1778.
3Okamatsu K, Tanano M, Sakai S, et al. Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndrome. Circulation, 2004,109:465-470.
4Cannon CP, Turpie AG. Unstable angina and non-St-elevation myocardial infarction. Initial antithrombotic therapy and early invasive strategy. Circulation, 2003,107:2640-2645.
5Morrow DA, Antman EM, Murphy SA, et al. The risk score profile: a novel approach to characterizing the risk of population enrolled in clinical studies. Eur Heart J, 2004, 25:1139-1145.
7Taneja AK, Collinson J, Flather MD, et al. Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK registry (Prospective registry of acute ischemic syndrome in the UK). Eur Heart J, 2004, 25:2013-2018.
8Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discivered during culprit vessel coronary intervention. Circulation, 2005, 111:143-149.
9Vetrovec GW. Optimizing percutaneous coronary intervention outcomes. The next steps. Circulation, 2005, 111:125-126.
10Cannon CP, Braunwald E, MaCabe CH, et al. Pravastatin or atorvastation evaluation and infection therapy-thrombolysis in myocardial infarction22? investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med, 2004, 350:1495-1504.
